Actively Recruiting
CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure
Led by NYU Langone Health · Updated on 2025-09-29
21
Participants Needed
1
Research Sites
560 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.
CONDITIONS
Official Title
CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult recipients (18 years and older) of allogeneic stem cell transplant from any donor type
- Documented graft dysfunction or failure including primary graft failure, poor graft function, or secondary graft failure
- Donor available to provide peripheral blood stem cells
- Negative pregnancy test within 7 days of infusion for women of childbearing potential
You will not qualify if you...
- Graft failure caused by disease relapse or disease progression
- Donor unavailable or unable to provide peripheral blood stem cells by apheresis
- Responding to conventional treatments such as hematopoietic growth factors
- Allergic reaction to murine proteins or iron dextran
- Women of childbearing potential with positive serum HCG
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
Research Team
K
Kiselle Mangalindan
CONTACT
K
Kelsey Stocker
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here